TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Teva Pharmaceuticals
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

A new study of 27 adults showed up to 77% of participants reported improvements in tardive dyskinesia symptoms while taking AUSTEDO or AUSTEDO XR, with 85% maintaining stable or improved mental health conditions.

Insights
BRK.A   neutral

Owns significant stake in SiriusXM despite the company's challenges


TEVA   positive

The company presented promising real-world data demonstrating patient improvements, highlighting their commitment to understanding and addressing tardive dyskinesia, which shows proactive medical research and patient-centric approach